Trial Information

Summary: A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation

You have/your child has been asked to participate in this research study because you are/your child is scheduled to receive a transplant of stem cells or bone marrow from an unrelated donor for a hematologic (blood or blood producing organ) disorder. The purpose of this study is to evaluate the safety and effectiveness of the combination of Sirolimus/tacrolimus and Thymoglobulin® for prophylaxis (preventive treatment) for graft-versus-host disease (GVHD) after transplant. Your/your child’s participation in this study is expected to last about 6 months for treatment and indefinitely after transplant for follow up.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: June 2, 2008 at 2:50:59 PM